NCT06677996View on ClinicalTrials.gov

A Phase 1 Study to Examine the Effects of Itraconazole After Single Dose Administration of Varegacestat (AL102) to Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

November 11, 2024

Primary Completion Date

December 30, 2024

Study Completion Date

May 7, 2025

Conditions
Healthy Volunteer
Interventions
DRUG

varegacestat

Experimental intervention

DRUG

Itraconazole (200 mg)

Intervention to evaluate DDI with experimental intervention

Trial Locations (1)

85289

Celerion, Tempe

Sponsors

Lead Sponsor

Immunome, Inc.
All Listed Sponsors
lead

Immunome, Inc.

INDUSTRY

NCT06677996 - A Phase 1 Study to Examine the Effects of Itraconazole After Single Dose Administration of Varegacestat (AL102) to Healthy Participants | Biotech Hunter | Biotech Hunter